Should children with osteogenesis imperfecta be treated with bisphosphonates?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 1, 2006, Pages 14-15

  Marini, Joan C ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Bisphosphonates; BMD; Neridronate; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; NERIDRONIC ACID; VITAMIN D;

BONE DENSITY; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NOTE; OSTEOGENESIS IMPERFECTA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 33646502801     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0075     Document Type: Note

References (5)

1. Whyte MP et al. (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457-463
2. Sakkers R et al. (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363: 1427-1431
3. Glorieux FH et al. (2004) Alendronate in the treatment of pediatric osteogenesis imperfecta. J Bone Miner Res 19 (Suppl 1): 1043
4. Letocha AD et al. (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20: 977-986
5. Uveges TE et al. (2004) Alendronate treatment of Brtl mouse model for osteogenesis imperfecta improved bone geometry and loading before fracture but decreased bone material quality and alters osteoblast morphology. Eur J Hum Genet 12 (Suppl 1): 1208